Glycaemic control with non-insulin therapies

Journal of Endocrinology, Metabolism and Diabetes of South Africa

Volumn 17, Issue 1, 2012, Pages

  Amod, Aslam ^a   Pirie, Fraser ^a   Dave, Joel ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

ACARBOSE; ANTIDIABETIC AGENT; BUFORMIN; DIPEPTIDYL PEPTIDASE IV INHIBITOR; EXENDIN 4; GLIBENCLAMIDE; GLICLAZIDE; GLIMEPIRIDE; GLIPIZIDE; GLITAZONE DERIVATIVE; GLUCAGON LIKE PEPTIDE 1 RECEPTOR AGONIST; GLUCOSE; HEMOGLOBIN A1C; INCRETIN; INSULIN; LINAGLIPTIN; LIRAGLUTIDE; METFORMIN; PHENFORMIN; SAXAGLIPTIN; SITAGLIPTIN; SULFONYLUREA DERIVATIVE; VILDAGLIPTIN; CHLORPROPAMIDE; ORAL ANTIDIABETIC AGENT; PIOGLITAZONE; ROSIGLITAZONE;

ABDOMINAL CRAMP; ACUTE HEART INFARCTION; BLOATING; CLINICAL PROTOCOL; DIABETES CONTROL; DIABETES MELLITUS; DIARRHEA; DRUG CONTRAINDICATION; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG INDICATION; DRUG MECHANISM; DRUG METABOLISM; DRUG PROTEIN BINDING; DRUG SAFETY; DRUG WITHDRAWAL; FLATULENCE; GASTROINTESTINAL SYMPTOM; GLOMERULUS FILTRATION RATE; GLUCOSE BLOOD LEVEL; GLYCEMIC CONTROL; HEMOGLOBIN BLOOD LEVEL; HUMAN; HYPOGLYCEMIA; LACTIC ACIDOSIS; LYMPHOCYTOPENIA; MAXIMUM PLASMA CONCENTRATION; MORTALITY; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; OPTIMAL DRUG DOSE; PANCREATITIS; RASH; REVIEW; RHINOPHARYNGITIS; SIDE EFFECT; URINARY TRACT INFECTION; WEIGHT GAIN; ALGORITHM; BLOOD GLUCOSE MONITORING; DRUG RELEASE; FLUID RETENTION; HEART FAILURE; HYPERSENSITIVITY REACTION; NAUSEA AND VOMITING; PREGNANCY DIABETES MELLITUS; SKIN MANIFESTATION; STOMACH PARESIS;

EID: 84864819137     PISSN: 16089677     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (54)

1. American Diabetes Association. Standards of Medical Care in Diabetes - 2012. Diabetes Care. 2012 35:S11-S63.
2. Canadian Diabetes Association. 2008 Clinical practice guidelines for the prevention and management of diabetes in Canada. Can J Diabetes. 2008;32 (Suppl 1):1-215.
3. Bailey CJ, Turner RC. Metformin. N Engl J Med. 1996;334(9):574.
4. UKPDS 34. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes. Lancet. 1998; 352: 854-865
5. Lipska KJ. Use of metformin in the setting of mild-to-moderate renal insufficiency. Diabetes Care. 2011;34:1431-7
6. Malmberg K. Intensive metabolic control by means of insulin in patients with diabetes mellitus and acute myocardial infarction (DIGAMI2): effects on mortality and morbidity. Eur Heart J. 2005;26:650-661
7. Eurich DT. Improved clinical outcomes associated with metformin in patients with diabetes and heart failure. Diabetes Care. 2005;28:2345-2351.
8. Misbin RI, Green L, Stadel BV, et al. Lactic acidosis in patients with diabetes treated with metformin. N Engl J Med. 1998, 338:265-266.
9. Rendell M. The role of sulphonylureas in the management of type 2 diabetes mellitus. Drugs. 2004;64(12):1339-1358.
10. Bennett K, James C, Hussain K. Pancreatic β-cell KATP channels: hypoglycaemia and hyperglycaemia. Rev Endocr Metab Disord. 2010;11:157-163.
11. Ter Braak EW, Appelman AM, Van der Tweel I, et al. The sulfonylurea glibenclamide induces impairment of glucagon and growth hormone responses during mild insulin-induced hypoglycemia. Diabetes Care. 2002;25:107-112.
12. Muller G, Satoh Y, Geisen K. Extrapancreatic effects of sulfonylureas: a comparison between glimepiride and conventional sulfonylureas. Diabetes Res Clin Pract. 1995;28(Suppl 1):S115-S137.
13. Briscoe VJ, Griffith ML, Davis SN. The role of glimepiride in the treatment of type 2 diabetes mellitus. Expert Opin Drug Metab Toxicol. 2010; 6(2):225-235.
14. Zhou S-F, Zhou Z-W, Huang M. Polymorphisms of human cytochrome P450 2C9 and the functional relevance. Toxicology. 2010;278:165-188.
15. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group. Lancet. 1998,352:837-853.
16. DeFronzo RA. Pharmacologic therapy for type 2 diabetes mellitus. Ann Intern Med. 1999;131:281-303.
17. ADVANCE Collaborative Group, Patel A, MacMahon S, Chalmers J, et al. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med. 2008;358:2560-2572.
18. Meinert CL, Knatterud GL, Prout TE, Klimt CR. A study of the effects of hypoglycemic agents on vascular complications in patients with adult-onset diabetes. II. Mortality results. Diabetes. 1970;19(Suppl):789-830.
19. Howes LG, Sundaresan P, Lykos D. Cardiovascular effects of oral hypoglycaemic drugs. Clin Exp Pharmacol Physiol. 1996;23:201-206.
20. Ballagi-Pordany G, Koszeghy A, Koltai MZ, et al. Divergent cardiac effects of the first and second generation hypoglycemic sulfonylurea compounds. Diabetes Res Clin Pract. 1990;8:109-114.
21. Zeller M, Danchin N, Simon D, et al. Impact of preadmission sulfonylureas on mortality and cardiovascular outcomes in diabetic patients with acute myocardial infarction. J Clin Endocrinol Metab. 2010;95:4993-5002.
22. Mitri J, Hamdy O. Diabetes medications and body weight. Expert Opin Drug Saf. 2009;8:573-584.
23. United Kingdom Prospective Diabetes Study Group. United Kingdom Prospective Diabetes Study 24: A 6-year randomized, controlled trial comparing sulfonylurea, insulin and metformin therapy in patients with newly diagnosed type 2 diabetes that could not be controlled with diet therapy. Ann Intern Med. 1998;128:165-175.
24. Rydberg T, Jonsson A, Roder M, Melander A. Hypoglycemic activity of glyburide (glibenclamide) metabolites in humans. Diabetes Care. 1994;17:1026-1030.
25. Holstein A, Plaschke A, Egberts E-H. Lower incidence of hypoglycaemia in patients with type 2 diabetes treated with glimepiride versus glibenclamide. Diabetes Metab Res Rev. 2001;17:467-473.
26. Tessier D, Dawson K, Tetrault JP, et al. Glibenclamide vs. gliclazide in type 2 diabetes of the elderly. Diabet Med. 1994;11:974-980.
27. Holstein A, Egberts E-H. Risk of hypoglycaemia with oral anti-diabetic agents in patients with type 2 diabetes. Exp Clin Endocrinol Diabetes. 2003;111:405-414.
28. Schernthaner G et al. GUIDE study: double-blind comparison of oncedaily gliclazide MR and glimepiride in type 2 diabetic patients. Eur J Clin Invest 2004; 34(8): 535-542
29. Holstein A, Hahn M, Patzer O, et al. Impact of clinical factors and CYP2C9 variants for the risk of severe sulfonylurea-induced hypoglycemia. Eur J Clin Pharmacol. 2011;67:471-476.
30. Burge MR, Sood V, Sobhy TA, et al. Sulphonylurea-induced hypoglycaemia in type 2 diabetes mellitus: a review. Diabetes Obesity and Metabolism 1999;1:199-206.
31. Nicholson W, Baptiste-Roberts K. Oral hypoglycaemic agents during pregnancy: the evidence for effectiveness and safety. Best Pract Res Clin Obstet Gynaecol. 2011;25:51-63.
32. Van de Laar FA, Lucassen PL, Akkermans RP, et al. Alpha-glucosidase inhibitors for type 2 diabetes mellitus. Cochrane Database Syst Rev(2). 2005:CD003639.
33. Chiasson JL, Josse RG, Hunt JA, et al. The efficacy of acarbose in the treatment of patients with non-insulin-dependent diabetes mellitus.A multicenter controlled clinical trial. Ann Intern Med. 1994;121(12):928.
34. Chiasson JL, Josse RG, Gomis R, et al STOP-NIDDM Trial Research Group. Acarbose treatment and the risk of cardiovascular disease and hypertension in patients with impaired glucose tolerance: the STOP-NIDDM trial. JAMA. 2003;290(4):486.
35. National Institute for Health and Clinical Excellence. CG87 Type 2 diabetes - newer agents (a partial update of CG66): NICE guideline [homepage on the Internet]. [cited 2011 Sep 22]. Available from: http://guidance.nice.org.uk/ CG87/NICEGuidance/doc/English.
36. ABCD position statement on incretin mimetics and DPP-4 inhibitors - 2009. Pract Diab Int. 2009; 26(5).
37. Clarifying the role of incretin-based therapies in the treatment of type 2 diabetes mellitus. Cin Ther. 2011;33(5):511-527.
38. Thong KY, Jose B, Sukumar N, et al. Safety, efficacy and tolerability of exenatide in combination with insulin in the Association of British Clinical Diabetologists nationwide exenatide audit. Diabetes Obes Metab. 2011;13(8):703-710.
39. Yoon NM, Cavaghan MK, Brunelle RL, Roach P. Exenatide added to insulin therapy: a retrospective review of clinical practice over two years in an academic endocrinology outpatient setting. Clin Ther. 2009;31(7):1511-1523.
40. Lehmann JM, Moore LB, Smith-Oliver TA, et al. An antidiabetic thiazolidinedione is a high affinity ligand for peroxisome proliferator activated receptor gamma (PPAR gamma). J Biol Chem. 1995;270:12953-12956.
41. Yki-Järvinen H. Thiazolidinediones. N Engl J Med. 2004;351:1106-1118.
42. Kahn SE, Haffner SE, Heise MA, et al. ADOPT Study Group. Glycemic durability of rosiglitazone, metformin or glyburide monotherapy. N Engl J Med 2006;355:2427-2443.
43. Kahn SE, Lachin JM, Zinman B, et al. Effects of rosiglitazone, glyburide and metformin on β-cell function and insulin sensitivity in ADOPT. Diabetes. 2011;60(5):1552-1560.
44. Nissen SE, Wolski K. Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. N Engl J Med. 2007;356:2457-2571.
45. Nissen SE, Wolski K. Rosiglitazone revisited. An updated meta-analysis of risk for myocardial infarction and cardiovascular mortality. Arch Intern Med. 2010;170(14):1191-1201.
46. Home PD, Pocock SJ, Beck-Nielsen H, et al. Rosiglitazone evaluated for cardiovascular outcomes in oral agent combination therapy for type 2 diabetes (RECORD): a multicentre, randomized, open-label trial. Lancet. 2009;373:2125-2135.
47. Dormandy JA, Charbonnel B, Eckland DJ, et al. Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive trial (PRO-spective pioglitazone Clinical Trial in macroVascular Events) a randomized controlled trial. Lancet. 2005;366:1279-1289.
48. Mazzone T, Meyer PM, Feinstein SB, et al. Effect of pioglitazone compared with glimepiride on carotid intima-media thickness in type 2 diabetes: a randomized trial. JAMA. 2006;296:2572-2581.
49. Nissen SE, Nicholls SJ, Wolski K, et al, for the PERISCOPE Investigators. Comparison of pioglitazone vs glimepiride on progression of coronary atherosclerosis in patients with type 2 diabetes: the PERISCOPE randomized controlled trial. JAMA. 2008;299:1561-1573.
50. Rubenstrunk A, Hanf R, Hum DW, et al. Safety issues and prospects for future generations of PPAR modulators. Biochim Biophys Acta. 2007;1771:1065-1081.
51. Lewis JD, Quesenberry CP, Ferrara A, et al. Risk of bladder cancer among patients treated with pioglitazone. Diabetes Care. 2011;34:916-922.
52. Ferrara A, Strom BL, Lewis JD, et al. Cohort study of pioglitazone and cancer incidence in patients with diabetes. Diabetes Care. 2011;34:923-929.
53. Agence Francaise de Securite Sanitaire des Produits de Sante. Spécialités pharmaceutiques contenant de la pioglitazone - Laboratoire TAKEDA - Retrait [homepage on the Internet]. c2011 [cited 2011 Sep 19]. Available from: http://www.afssaps.fr/Infos-desecurite/ Retraits-de-lots-et-de-produits/Specialites-pharmaceutiques-contenant- de-la-pioglitazone-Laboratoire-Takeda-Retrait.
54. Medicines Control Council [homepage on the Internet]. c2011 [cited XXX]. Available from: http://www.mccza.com/ genericDocuments/10.07-Press-Release.